专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070037746A1 Novel compounds 审中-公开
标题翻译：新型化合物
公开(公告)号：US20070037746A1
公开(公告)日：2007-02-15
申请号：US11497072
申请日：2006-08-01
申请人： Henrik Ostergaard , Egon Persson
发明人： Henrik Ostergaard , Egon Persson
IPC分类号： A61K38/37 , C07K14/75
CPC分类号： A61K38/4846 , C12N9/6437 , C12N9/647 , C12Y304/21021 , Y02A50/473 , Y02A50/481
摘要： The present invention relates to novel coagulation factor FVIIa polypeptides.
摘要翻译：本发明涉及新型凝血因子FVIIa多肽。

2. 发明申请

US20090252720A1 Prolonged FIX Analogues and Derivatives 审中-公开
标题翻译：长期的FIX类似物和衍生物
公开(公告)号：US20090252720A1
公开(公告)日：2009-10-08
申请号：US12302167
申请日：2007-05-24
申请人： Henrik Ostergaard , Ole Hvilsted Olsen , Henning Ralf Stennicke , Thomas Dock Steenstrup
发明人： Henrik Ostergaard , Ole Hvilsted Olsen , Henning Ralf Stennicke , Thomas Dock Steenstrup
IPC分类号： A61K38/48 , C12N9/76
CPC分类号： C12N9/96 , A61K38/00 , A61K47/60 , C12N9/644 , C12Y304/21022
摘要： The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue.
摘要翻译：本发明涉及FIX类似物，其在活化前与血浆中循环时间增加相比，与天然FIX相比（注射至患者一周后，与起始活性相比，FIX活性至少保持约5％注射后达到峰值）。所要求保护的FIX类似物包括插入的半胱氨酸残基，其通过与增加FIX类似物的分子量的化学基团缀合进一步修饰。

3. 发明申请

US20090055942A1 Human Coagulation Factor VII Polypeptides 审中-公开
标题翻译：人凝血因子VII多肽
公开(公告)号：US20090055942A1
公开(公告)日：2009-02-26
申请号：US12066619
申请日：2006-09-14
申请人： Henrik Ostergaard , Ole Hvilsted Olsen , Katrine Skaarup Larsen , Henning Stennicke
发明人： Henrik Ostergaard , Ole Hvilsted Olsen , Katrine Skaarup Larsen , Henning Stennicke
IPC分类号： A01K67/00 , C07K14/00 , C07H21/04 , C12N15/63 , A01H5/00 , A61K38/17 , C12P21/06 , C12N5/00 , C12N5/06 , C12N5/08
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to novel human coagulation Factor Vila variants having substitutions of one or more amino acids at a position selected from the group consisting of position 172, 173, 175, 176, 177, 196, 197, 198, 199, 200, 203, 235, 237, 238, 239, 240, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 297, 299, 319, 320, 321, 327, 341, 363, 364, 365, 366, 367, 370, 373 corresponding to amino acid positions of SEQ ID NO:1 and wherein said Factor VII polypeptide exhibits increased resistance to inactivation by an endogenous inhibitor of said FVII polypeptide relative to wild-type human FVIIa.
摘要翻译：本发明涉及新的人凝血因子VIIa变体，其在选自下列的位置中具有一个或多个氨基酸的取代：位置172,173,175,176,177,196,197,198,199,200,2203 ，235,237,238,239,240,286,287,288,289,290,291,292,293,294,295,297,29,39,320,321,327,341,363,364,365,346 ，366,367,370,373，其对应于SEQ ID NO：1的氨基酸位置，并且其中所述因子VII多肽相对于野生型人FVIIa表现出对所述FVII多肽的内源性抑制剂的失活的增强的抗性。

4. 发明申请

US20080227691A1 Blood Coagulation FVIII Analogues 审中-公开
标题翻译：血液凝固FVIII类似物
公开(公告)号：US20080227691A1
公开(公告)日：2008-09-18
申请号：US11910349
申请日：2006-04-03
申请人： Henrik Ostergaard , Gert Bolt , Thomas Dock Steenstrup
发明人： Henrik Ostergaard , Gert Bolt , Thomas Dock Steenstrup
IPC分类号： A61K38/37 , C07K14/755 , A61P7/00
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.
摘要翻译：本发明涉及FVIII类似物，FVIII类似物在活化至少约二分之一的天然FVIII之前在血流中具有循环时间，并且在注射至患者后一周内保留FVIII活性的至少约5％注射后达到初始活动峰值。要求保护的FVIII类似物包括通过引入至少一个N-糖基化位点或通过引入至少一个Cys残基在或在空间上靠近A2中的清除位点来定位破坏FVIII分子中的一个或多个清除位点域或其组合。插入的半胱氨酸残基可以通过与增加FVIII类似物的分子量的化学基团缀合来进一步修饰。

5. 发明申请

US20060205036A1 Coagulation Factor VII polypeptides 审中-公开
标题翻译：凝血因子VII多肽
公开(公告)号：US20060205036A1
公开(公告)日：2006-09-14
申请号：US11367189
申请日：2006-03-03
申请人： Henrik Ostergaard , Soren Bjorn , Egon Persson
发明人： Henrik Ostergaard , Soren Bjorn , Egon Persson
IPC分类号： C12P21/04 , C07H21/04 , A61K38/36 , C07K14/745
CPC分类号： C07K14/745 , A61K38/00 , C12N9/6437 , C12N9/647 , C12Y304/21021
摘要： The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
摘要翻译：本发明涉及新型凝血因子VII多肽，编码这种多肽的多核苷酸构建体，以及包含和表达多核苷酸，药物组合物，用途和治疗方法的载体和宿主细胞。

6. 发明授权

US08633300B2 Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine 失效
标题翻译：包含至少一种非天然半胱氨酸的工程化蛋白质的选择性还原和衍生化
公开(公告)号：US08633300B2
公开(公告)日：2014-01-21
申请号：US11917772
申请日：2006-06-19
申请人： Henrik Ostergaard , Anders Klarskov Petersen
发明人： Henrik Ostergaard , Anders Klarskov Petersen
IPC分类号： A61K35/14 , C07K1/00
CPC分类号： C07K1/113 , C07K1/1133 , C07K14/745
摘要： The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.
摘要翻译：本发明涉及包含至少一种非天然半胱氨酸的重组制备的工程改造蛋白的选择性还原和衍生化方法，其中还原反应在氧化还原缓冲剂存在下或在三芳基膦还原剂存在下进行。

7. 发明申请

US20090041744A1 Dimeric and Multimeric FVIIa Compounds 审中-公开
标题翻译：二聚体和多聚体FVIIa化合物
公开(公告)号：US20090041744A1
公开(公告)日：2009-02-12
申请号：US11917561
申请日：2006-06-19
申请人： Henrik Ostergaard , Henning Ralf Stennicke
发明人： Henrik Ostergaard , Henning Ralf Stennicke
IPC分类号： A61K38/43 , C07K14/00 , A61P7/00
CPC分类号： C12N9/6437 , C12Y304/21021
摘要： The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides.
摘要翻译：本发明涉及包含共价连接的至少两个FVIIa多肽的二聚体或多聚体FVIIa化合物，以保留FVIIa多肽的内在催化活性。

8. 发明申请

US20080200651A1 Selective Reduction and Derivatization of Engineered Proteins Comprising at Least One Non-Native Cysteine 失效
标题翻译：包含至少一个非天然半胱氨酸的工程蛋白质的选择性还原和衍生
公开(公告)号：US20080200651A1
公开(公告)日：2008-08-21
申请号：US11917772
申请日：2006-06-19
申请人： Henrik Ostergaard , Anders Klarskov Petersen
发明人： Henrik Ostergaard , Anders Klarskov Petersen
IPC分类号： C07K1/113
CPC分类号： C07K1/113 , C07K1/1133 , C07K14/745
摘要： The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.
摘要翻译：本发明涉及包含至少一种非天然半胱氨酸的重组制备的工程改造蛋白的选择性还原和衍生化方法，其中还原反应在氧化还原缓冲剂存在下或在三芳基膦还原剂存在下进行。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式